

EIB-20240723 RWANDA VACCINE ECOSYSTEM STRENGTHENING (MAV)



Quick Facts

Countries	Rwanda
Financial Institutions	European Investment Bank (EIB)
Status	Approved
Bank Risk Rating	U
Voting Date	2025-10-08
Borrower	BioNTech Rwanda Ltd.
Sectors	Education and Health, Industry and Trade
Investment Type(s)	Grant
Investment Amount (USD)	\$ 40.70 million
Project Cost (USD)	\$ 381.44 million



Project Description

According to the Bank's website, the operation consists in a EUR 35m investment grant to be blended with the EIB loan under the operation 2024-0438: Rwanda M-RNA Manufacturing Hub (HDX).

The aim is to support the establishment of a regional research and development (R&D;) and manufacturing site for vaccines in Rwanda to strengthen the vaccine R&D; ecosystem Africa.

The manufacturing site will focus on the delivery of an African commercial-scale manufacturing plant, initially producing an already approved vaccine with the intention of eventually manufacturing other vaccines which are still in clinical development phase.

In detail, the manufacturing site will commercially manufacture products, and operate as a contract manufacturing service for African partners by manufacturing products for clinical research purposes that comply with the principles and guidelines of good manufacturing practices.



Early Warning System Project Analysis

According to the Bank's website, the EIB will require the project's compliance with the relevant environmental legislation and alignment of the EIB's Environmental and Social principles and standards. Additional project activities, such as R&D, are expected to be carried out in existing facilities that are already used for similar purposes or are investments of intangible nature and hence are not expected to create significant impact on the environment.



EIB-20240723

Investment Description

• European Investment Bank (EIB)

A EUR 35m investment grant to be blended with the EIB loan under the operation 2024-0438: Rwanda M-RNA Manufacturing Hub (HDX)

Private Actors Description

Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. *BioNTech Rwanda*, established in 2022, will manage the Kigali facility. To date, BioNTech has made a triple digit million Euro investment in the establishment of its mRNA manufacturing facility in Kigali and plans to continue investingover the next years.



EIB-20240723

Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	BioNTech Rwanda Ltd.	Client	-
_	_	_	_	BioNTech SF	Parent Company	_



Contact Information

No contacts available at the time of disclosure.

ACCESS TO INFORMATION

You can submit an information request for project information at: https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm

ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: complaints@eib.org, by completing the online complaint form available at the following address: http://www.eib.org/complaints/form via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check:

http://www.eib.org/attachments/strategies/complaints mechanism policy en.pdf

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces





Other Related Projects

• EIB-20240438 RWANDA M-RNA MANUFACTURING HUB (HDX)